🔗 Share this article The Global Health Body Sounds Warning Over Acute Shortage of Obesity Jabs Under 10% of people who could benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it issues its inaugural advice on the therapies. Given more than one billion people worldwide now living with obesity, it is advocating for broader and more equitable access to this class of drugs. According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "The latest guidance acknowledges that excess weight is a long-term condition that can be managed with thorough and continuous support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are major barriers to broad availability to the treatments that can aid individuals in losing significant weight, notes the organization. GLP-1 Therapy Scarcity Even in the current most favorable case, the production of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, according to the health organization. The advice urges nations and manufacturers to widen availability, through approaches including patent sharing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is set to lapse in several nations in 2026. The Way Weight-Loss Drugs Operate The injections imitate a body's own hormone to reduce digestion speed, curb appetite and increase feelings of fullness so users eat less. Patients typically begin shedding pounds in the initial weeks of commencing the regular doses. Evidence points to people may see weight return after a year of stopping the treatment, because their typical food cravings come back. To be carrying excess weight elevates your risk for contracting diseases, like diabetes, cardiovascular issues, stroke, and specific cancers. Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, per the health agency.
Under 10% of people who could benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it issues its inaugural advice on the therapies. Given more than one billion people worldwide now living with obesity, it is advocating for broader and more equitable access to this class of drugs. According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "The latest guidance acknowledges that excess weight is a long-term condition that can be managed with thorough and continuous support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are major barriers to broad availability to the treatments that can aid individuals in losing significant weight, notes the organization. GLP-1 Therapy Scarcity Even in the current most favorable case, the production of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, according to the health organization. The advice urges nations and manufacturers to widen availability, through approaches including patent sharing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is set to lapse in several nations in 2026. The Way Weight-Loss Drugs Operate The injections imitate a body's own hormone to reduce digestion speed, curb appetite and increase feelings of fullness so users eat less. Patients typically begin shedding pounds in the initial weeks of commencing the regular doses. Evidence points to people may see weight return after a year of stopping the treatment, because their typical food cravings come back. To be carrying excess weight elevates your risk for contracting diseases, like diabetes, cardiovascular issues, stroke, and specific cancers. Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, per the health agency.